Diagnostic Value of Serum sST2 and MicroRNA-29a in Ovarian Cancer: A Dual-Biomarker Pilot Study.

Fatma Tuba Akdeniz, Zerrin Barut, Orcun Avsar, Selvi Duman Bakırezer, Rukset Attar, Turgay Isbir

Abstract read

In one paragraph

Article in Current issues in molecular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Fatma Tuba AkdenizDepartment of Genetics and Bioengineering, Faculty of Engineering and Natural Sciences, Istanbul Okan University, Istanbul 34959, Türkiye.ORCID 0000-0002-6076-0509

Zerrin BarutDepartment of Basic Medical Sciences, Faculty of Dentistry, Antalya Bilim University, Antalya 07190, Türkiye.ORCID 0000-0002-6289-5562

Orcun AvsarDepartment of Molecular Biology & Genetics, Faculty of Engineering and Natural Sciences, Hitit University, Corum 19030, Türkiye.ORCID 0000-0003-3556-6218

Selvi Duman BakırezerDepartment of Basic Medical Sciences, Faculty of Medicine, Yeditepe University, Istanbul 34755, Türkiye.ORCID 0000-0003-1135-8182

Rukset AttarDepartment of Obstetrics and Gynecology, School of Medicine, Yeditepe University, Istanbul 34755, Türkiye.ORCID 0000-0001-8770-9562

Turgay IsbirDepartment of Molecular Medicine, Institute of Health Science, Yeditepe University, Istanbul 34755, Türkiye.ORCID 0000-0002-7350-6032

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian cancer is frequently diagnosed at an advanced stage due to non-specific symptoms, contributing to high mortality. The limited diagnostic performance of current serum assays in early disease underscores the need for complementary circulating biomarkers. Circulating microRNAs and inflammation-related markers are promising candidates. Although miRNAs are implicated in cancer diagnostics, the role of miRNA-29a in ovarian cancer remains underexplored. Given that sST2 is elevated in several malignancies and is a direct target of miRNA-29a, concurrent evaluation may be informative. This pilot study compared serum miRNA-29a and sST2 levels in 23 ovarian cancer patients and 22 healthy female controls. miRNA-29a expression was quantified by real-time PCR (2

Indexed as

biomarkerELISAmicroRNA-29aovarian cancerqPCRreceiver operating characteristic analysissST2

Identifiers

PMID41614943

DOI10.3390/cimb48010113

PMCPMC12839895

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.